NuVasive Receives a Hold from Leerink Partners

By Carrie Williams

In a report released today, Richard Newitter from Leerink Partners maintained a Hold rating on NuVasive (NASDAQ: NUVA), with a price target of $52. The company’s shares closed yesterday at $48.23, close to its 52-week low of $44.62.

According to, Newitter is a top 100 analyst with an average return of 26.5% and a 70.7% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.

NuVasive has an analyst consensus of Strong Buy, with a price target consensus of $68.13.

NuVasive’s market cap is currently $2.46B and has a P/E ratio of 40.53. The company has a book value ratio of 3.2519.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuVasive, Inc. is medical device company, which engages in the development of minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery. It offers cervical and spine fusion surgery, cervical plating, and posterior fixation products. The company was founded by Alexis V.